Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Solventum

Solventum Stock Earns RS Rating Upgrade

Solventum shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Solventum Stock Outlook: Is Wall Street Bullish or Bearish?

Solventum has outperformed the broader market over the past year, yet analysts remain cautious about the stock’s prospects.

Barchart

Solventum Meets 80-Plus Relative Strength Rating Benchmark

A Relative Strength Rating upgrade for Solventum shows improving technical performance.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Solventum Scores Relative Strength Rating Upgrade; Hits Key Threshold

Solventum sees its Relative Strength Rating enter the 80-plus level.

Investors Business Daily

Here's What to Expect From Solventum’s Next Earnings Report

Solventum is expected to unveil its first quarter results in the upcoming month, and analysts predict its bottom line to suffer in double digits.

Barchart

Solventum Stock: Is SOLV Outperforming the Healthcare Sector?

Despite outpacing the healthcare sector over the past year, analysts remain cautious about the stock’s prospects.

Barchart

Solventum Shows Market Leadership With Jump To 92 RS Rating

Solventum shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Solventum Shows Market Leadership With Jump To 85 RS Rating

A Relative Strength Rating upgrade for Solventum shows improving technical performance.

Investors Business Daily

Are Wall Street Analysts Predicting Solventum Stock Will Climb or Sink?

Although Solventum has outperformed the broader market over the past year, Wall Street analysts remain cautious about the stock's growth potential.

Barchart

Earnings Preview: What to Expect from Solventum’s Report

Recently spun-off healthcare major Solventum is expected to announce its fourth-quarter results in the upcoming month and analysts predict an EPS of $1.31.

Barchart

Solventum Earns Relative Strength Rating Upgrade

Solventum shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Is Solventum Stock Underperforming the Dow?

Solventum has underperformed compared to the Dow index over the past three months, though analysts remain cautious about the stock’s growth prospects.

Barchart

Honeywell Mulls A Move That May Herald Aerospace Megamerger

A standalone Honeywell aerospace business could be worth up to $120 billion. Honeywell stock rose on Monday.

Investors Business Daily

A Peek at Cooper Companies's Future Earnings

Cooper Companies (NYSE:COO) is gearing up to announce its quarterly earnings on Thursday, 2024-12-05. Here's a quick overview of what investors should know before the release.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

5 Analysts Have This To Say About Solventum

In the preceding three months, 5 analysts have released ratings for Solventum (NYSE:SOLV), presenting a wide array of perspectives from bullish to bearish.

Barchart

Is Wall Street Bullish or Bearish on Solventum Stock?

Due to Solventum’s underperformance relative to the broader S&P 500 Index over the past six months, Wall Street analysts remain cautious about the stock’s prospects.

Barchart

Solventum's Quarterly Earnings Preview: What You Need to Know

Solventum is scheduled to report its third-quarter results next month.

Investors Business Daily

Solventum Stock Earns 81 RS Rating

Solventum sees its Relative Strength Rating move into the 80-plus level.

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Is Solventum Stock Outperforming the Nasdaq?

Solventum outperformed the broader market recently, but Wall Street analysts remain cautious about the stock’s prospects.

Barchart

Are Wall Street Analysts Bullish on Solventum Stock?

Solventum has underperformed the broader market over the past three months, and Wall Street analysts are cautious about the stock's potential.

Barchart

Solventum’s Q2 2024 Earnings: What to Expect

Solventum is gearing up to unveil its second-quarter earnings next month. Here’s what analysts are predicting.

Investors Business Daily

11 Stocks Now Thrive As The Magnificent Seven Fall Apart

It's been a rough couple of weeks for the Magnificent Seven stocks. But it's been a boon for some other S&P 500 stocks.

Barchart

What to Expect From 3M’s Q2 2024 Earnings Report

3M is expected to release its second-quarter earnings later this month, and analysts project a double-digit profit dip.

Barchart

3 Dividend Kings That Cut (Or Will Cut) Their Dividends

Dividend aristocracy isn't always a sure thing. Here are 3 companies that have been or will be booted from the coveted king's list.

Barchart

After Its Historic Dividend Cut, Is 3M Stock Still Worth Buying?

3M stock is a Dividend King no more, as the company slashed its payout following the Solventum spinoff. Is the stock still a buy for investors seeking passive income?

1 2

People

Mike Roman

40 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Walgreens Boots Alliance

Read news from The Economist, FT, and more,
with one subscription

Places

United States

276,974 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.